期刊文献+

PD-ECGF在宫颈癌中的表达及与新生血管的关系 被引量:1

Expression of Platelet-derived Endothelial Cell Growth Factor in Cervical Cancers and its Relationship to Angiogenesis
下载PDF
导出
摘要 [目的]探讨宫颈癌中血小板源内皮细胞生长因子 (PD ECGF)表达与新生血管形成的关系。[方法]用免疫组化技术检测45例宫颈癌实质细胞和间质细胞中PD ECGF的表达和微血管计数(MVC)。[结果]鳞癌癌细胞中PD ECGF表达明显高于腺癌 ,其表达率分别为82.4 %和17.6 % ,二者比较差异显著 (P<0.01) ;腺癌间质细胞PD ECGF阳性率明显高于鳞癌 ,分别为72.7%和11.8 % ,二者比较具有显著性差异 (P<0.01)。间质细胞中PD ECGF阳性表达与高MVC值、3年和5年存活率均有显著相关性。[结论]间质细胞中PD ECGF具有更强的促血管生成作用 。 To observe the expression of platelet derived endothelial cell growth factor (PD ECGF) separately in stroma cells,and in cancer cells, and its relationship to the angiogenesis. Expression of PD ECGF in cancer cells and in stroma cells with microvessal count(MVC) were studied by immunohistochemical technology. Immunopositivity for PD ECGF in stroma cells was significantly higher in cervical adenocarinoma(CAC) than that in cervical squamous cell carcinoma(CSC) (P<0.01). Expression of PD ECGF in cancer cells was significantly higher in CSC than that in CAC (P<0.01). High MVC was closely correlated with positive PD ECGF expression in stroma cells (P<0.05).The survival rate in patients with positive PD ECGF expression in stroma cells was significantly lower than those with positive PD ECGF expression in cancer cells (P<0.01). [Conclusions]The expression of PD ECGF in stroma cells may play a crucial role in the promotion of angiogenesis, we propose that angiogenic factors may be different in various types of cervical cancers.
出处 《肿瘤学杂志》 CAS 2001年第5期283-285,共3页 Journal of Chinese Oncology
关键词 血小板源内皮细胞生长因子 微血管计数 宫颈肿瘤 免疫组化法 新生血管 endothelial cell growth factor microvessal count cervix neoplasmas
  • 相关文献

参考文献10

  • 1Tokumo K,Kodama J,Seki N,et al.Different angiogenic pathways in human cervical cencer[].Gynecologic Oncology.1998
  • 2Seki N,Kodama J,Hongo A,et al.Angiogenesis and platelet- derived endothelial cell growth factor/ thymidine phosphrylase expression in endometrial cancer[].International Journal of Oncology.1999
  • 3Moghaddam A,Bicknell R.Expression of platelet-derived endothelial cell growth factor in Escherichia Coli and confirmation of its thymidine phosphorylase activity[].Biochemical Journal.1992
  • 4Zhou J,Tang Z,Fang J.The expression of platelet_derived endothelial cell growth factor in liver cancer[].Chung Hua I Hsuech Tsa Chih.2000
  • 5Kodama J,Yoshinouchi M,Hongo A,et al.Angiogenesis and platelet_derived endothelial cell growth factor/ thymidine phosphorylase explession in cervical cancer[].International Journal of Oncology.1999
  • 6Tang W,Wang X,Utsunomiya H,et al.TP expression in tumor stroma of uterine cervical carcinoma: histological features and MVD[].Cancer Letters.2000
  • 7Barton GJ,Ponting CP,Spraggon C,et al.Human platelet-derived endothedial cell growth factor is homologous to Escherichia coli thymidine phosphorylase[].Protein Science.1992
  • 8Miyzono K,Okabe T,Urabe A.Purification of plateletderived endothdial cell growth factor[].Journal of Biological Chemistry.1987
  • 9Griffith L,Stratford IL.Platelet_derived endothelial cell growth factor/ thymidine phosphorylase in tumor growth and response to therapy[].British Journal of Cancer.1997
  • 10Folkman J.Tumor angiogenesis and tissue factor[].Nature Medicine.1996

同被引文献7

  • 1于黎明,胡蓉.宫颈鳞癌组织中PD-ECGFmRNA与PD-ECGF的表达及临床意义[J].实用妇产科杂志,2005,21(3):151-153. 被引量:3
  • 2Leitzel K,Teramoto Y,Sampson E,et al.Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients.J Clin Oncol,1992,10:1436-1443.
  • 3Koizumi W,Saigenji K,Nakamaru N,et al.Prediction of response to 5′-deoxy-5-fluorouridine (5′-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine hosphorylase/platelet-derived endothelial cell growth factor.Oncology,1999,56:215-222.
  • 4Slamon DJ,Leyland-Jones B,Shak S,et al.Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N Engl J Med,2001,344:783-792.
  • 5Yu D,Wolf JK,Scanlon M,et al.Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.Cancer Res,1993,53:891-898.
  • 6Cobleigh MA,Vogel CL,Tripathy D,et al.Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.J Clin Oncol,1999,17:2639-2648.
  • 7罗衡桂,杨竹林,丁应文,李永国,马铁祥,王力,王云.胰腺癌中三种血管生长因子受体的表达研究[J].中华消化杂志,2002,22(8):467-469. 被引量:9

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部